@JAMAplusAI
Account based inUnited States
About this account
- Account based in
- United States
- Connected via
- Web
Account-level information from X, not a live location or the device used for a specific post.
JAMA+ AI is a window into the scientific content, educational reviews, and commentary on AI & medicine published across the @JAMANetwork family of journals.
Chicago, IL
Joined September 2024
- Tweets428
- Following168
- Followers795
- Likes18
Pinned Tweet
Announcing the launch of JAMA+ AI, an engaging, interactive channel that amplifies the best of the JAMA Network’s content exploring the science of artificial intelligence and digital medicine and its application in health and health care. ja.ma/3By7x4t
Congratulations to @JAMAplusAI Editor in Chief Roy Perlis, MD, MSc, on his appointment as Director of @UCSF_BCHSI and Priscilla Chan and Mark Zuckerberg Distinguished Professor at @UCSF.
ja.ma/4hTOWTg
JAMA+ AI retweeted
We are pleased to announce the appointment of Roy H. Perlis, MD, MSc, as director of @UCSF_BCHSI effective February 1, 2027. Read more about Dr. Perlis: medschool.ucsf.edu/news/anno…
🎙️ In the latest episode of JAMA+ AI Conversations, Roy Perlis, MD, MSc, spoke with Rochelle Walensky, MD, MPH, about how differences in administrative burden, electronic health record use, and patient messaging could shape who benefits from #AI.
ja.ma/47pkQkq
🎙️ In this episode of JAMA+ AI Conversations, Yulin Hswen, ScD, MPH, spoke with Bon Ku, MD, MPP, program manager at @ARPA_H about how simulation-based testing may help assess artificial intelligence systems before they are used in real-world care.
ja.ma/3VPgoZF
📊 Research Summary: Among adults with established #atherosclerotic #cardiovascular disease or high cardiovascular risk and recent #Statin nonadherence, digital outreach improved 14-day statin refill vs usual communication.
ja.ma/4cNvBAm
💬 Editorial: Digital outreach by nonsecure email, short message service, or secure portal messaging improved #Statin refill rates among patients with established atherosclerotic cardiovascular disease or high #cardiovascular risk and recent nonadherence.
ja.ma/4h5y5Ls
Among adults with established #AtheroscleroticCardiovascularDisease or high cardiovascular risk and recent #Statin nonadherence, digital outreach improved 14-day statin refill vs usual communication.
🔗 ja.ma/4yCk2o3
Featured in @washingtonpost: JAMA and JAMA+ AI Associate Editor Yulin Hswen, ScD, MPH, discussed her recent @JAMANetworkOpen study examining the gap between women's reported #menopause experiences and what is documented in #clinicalcare.
ja.ma/4iq1iDj
Read the @JAMANetworkOpen article, “Divergence in Menopause Symptom Narratives Between Online and Clinical Settings”:
🔗 ja.ma/4gWtjA0
➡️ Interested in learning more about the role of artificial intelligence and digital #medicine in #health care?
Follow @JAMAplusAI and subscribe to the newsletter for accessible, timely #AI content: ja.ma/4rbUXxQ
Trying to build your #AI knowledge?
The JAMA+ AI Editors have curated resources to understand key concepts in AI in medicine, along with must-read AI articles from across the JAMA Network.
📌 Explore JAMA+ AI Resources: ja.ma/4qY3HqV
💬 Editor's Note by JAMA Deputy Editors Preeti Malani, MD, MSJ, and Joseph Ross, MD, MHS: As generative #AI tools become more advanced and accessible, transparent reporting and updated editorial guidance are needed to ensure research integrity.
ja.ma/3UxO65y
JAMA+ AI is a window into the reviews and commentary on AI and medicine published across JAMA, JAMA Network Open, and the 11 JAMA specialty journals.
Editor in Chief Roy Perlis, MD, MSc, curates the content delivered directly to your inbox.
Learn more: jamanetwork.com/channels/ai
💬 Perspective: Much of today’s #WearableData may function as results of unknown significance, appearing clinically useful without clear evidence, reference ranges, or defined roles in diagnosis and treatment.
ja.ma/4qirYrJ
ALT JAMA article published August 3, 2026, titled \"Sorting Results of Unknown Significance\u2014A Framework for Clinicians Navigating Wearable Data in the AI Era.\" It features a table classifying patient-generated and device-derived health data by clinical validity and recommended clinical actionability.
💬 Viewpoint: Under the US Food and Drug Administration January 2026 guidance, many low-risk #DigitalHealth tools fall outside medical device oversight, but some may still influence health decisions without clear evidence standards.
ja.ma/4fWTCHa
🎙️@JAMAplusAI Conversations: JAMA+ AI Editor in Chief Roy Perlis, MD, MSc, and Joseph Geraci, PhD, discussed how artificial intelligence may shape #ClinicalTrials and how regulators may evaluate trials using #AI #biomarkers.
🔗 ja.ma/4wY1YUX
💬 Perspective: #GenerativeAI may improve #ClinicalDecisionSupport when it synthesizes decision-relevant patient context, but outputs should remain grounded in curated sources with source attribution and deterministic verification.
ja.ma/4g4LEdK
ALT JAMA article by Liu, Peterson, Wright, published July 23, 2026. A flowchart titled 'How Generative AI Should Transform Clinical Decision Support' compares current Clinical Decision Support (CDS) with LLM-enabled CDS across data, delivery, and governance, also outlining key risks.
💬 Editor's Note by JAMA Executive Editor Gregory Curfman, MD: The @FDA and the Federal Trade Commission provide limited oversight for low-risk #DigitalHealth wellness devices, aiming to preserve innovation while requiring truthful, substantiated claims.
ja.ma/4z9DDNw
Machine learning analysis of patient-clinician conversations identified cognitive impairment with sensitivity 68% and specificity 64%, supporting passive speech-based screening in routine #PrimaryCare. ja.ma/3S7nTKc
